Accolades for Dr. Lanctôt in Clinical Trials

Nov 16, 2020

Congratulations to Dr. Krista Lanctôt, recipient of the 2020 Irma M. Parhad Award for Excellence from the Consortium of Canadian Centres for Clinical Cognitive Research!

This prestigious award recognizes Dr. Lanctôt’s broad and important research contributions to the treatment of behavioural and psychological symptoms of dementia. She has made particularly notable contributions to understanding and treating apathy and agitation in Alzheimer’s disease - investigating the efficacy and safety of antidepressants, anticonvulsants, beta-blockers, and cannabinoids.

Dr. Lanctot’s recently published, positive study of nabilone, a synthetic cannabinoid, was awarded the “Most Impactful Paper of 2019” at the Alzheimer’s Association International Conference in August this year. The results of the study have led to funding for a phase 3, placebo-controlled trial of nabilone to treat agitation in AD.

Other important contributions by Dr. Lanctôt have included Clinical Practice Guidelines for dementia and post-stroke cognitive impairment. She has participated in and/or chaired several consensus conferences in these areas and her publications related to the pharmacological management of Alzheimer’s Disease from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD) are used frequently by specialists and primary care physicians to treat dementia patients.

Dr. Lanctôt is a Professor of Pharmacology & Toxicology and Psychiatry at the Temerty Faculty of Medicine. She is a Senior Scientist in the Brain Sciences Research Program at Sunnybrook Health Sciences Centre, Head of the Neuropsychopharmacology Research at Sunnybrook Research Institute, and the Executive Director of the Medical Outcomes and Research in Economics Research Centre.

Read more: http://c5r.ca/imra-m-parhad-award-for-excellence/2020-dr-krista-lanctot/